Nadroparin Sodium Activates Nrf2/HO-1 Pathway in Acetic Acid-Induced Colitis in Rats

dc.contributor.authorYalniz, Mehmet
dc.contributor.authorDemirel, Ulvi
dc.contributor.authorOrhan, Cemal
dc.contributor.authorBahcecioglu, Ibrahim Halil
dc.contributor.authorOzercan, Ibrahim Hanefi
dc.contributor.authorAygun, Cem
dc.contributor.authorŞahin, Kazım
dc.date.accessioned2026-08-12T17:46:36Z
dc.date.issued2012
dc.departmentFırat Üniversitesi
dc.description.abstractEffects of nadroparin sodium, a low molecular weight heparin, in colitis was investigated by analyzing proteins implicated in nuclear factor E2-related factor-2/heme oxygenase-1 (Nrf2/HO-1) and nuclear factor kappa B (NF-kappa B) pathways. Twenty-eight rats were used. Colitis was induced by acetic acid (AA). Nadroparin sodium was given to prevention and treatment groups in addition to AA. Colitis was assessed histologically and levels of proteins were analyzed with Western blot. Nadroparin not only prevented and ameliorated the AA-induced colitis histopathologically but also decreased expression of colon NF-kappa B, activator protein-1, cyclooxygenase-2, tumor necrosis factor-alpha, and IL-6, which were significantly increased in group AA compared to control. The accumulation of Nrf2 in nuclear fraction and HO-1 found low in group AA was increased with nadroparin (p < 0.05). The mean malondialdehyde level increased with AA and was decreased significantly with nadroparin prevention and treatment (p < 0.001). Nadroparin sodium has both protective and therapeutic effects against colonic inflammation via exerting anti-oxidative and anti-inflammatory effects by modulating Nrf2/HO-1 and NF-kappa B pathways.
dc.description.sponsorshipFirat University Scientific Research Projects Unit [2109]
dc.description.sponsorshipThis study was supported by Firat University Scientific Research Projects Unit with project number 2109.
dc.identifier.doi10.1007/s10753-012-9431-z
dc.identifier.endpage1221
dc.identifier.issn0360-3997
dc.identifier.issn1573-2576
dc.identifier.issue3
dc.identifier.orcid0000-0002-1329-3143
dc.identifier.orcid0000-0003-4138-7689
dc.identifier.orcid0000-0001-7776-4154
dc.identifier.orcid0000-0001-9542-5244
dc.identifier.pmid22350949
dc.identifier.scopus2-s2.0-84863798193
dc.identifier.scopusqualityQ1
dc.identifier.startpage1213
dc.identifier.urihttps://doi.org/10.1007/s10753-012-9431-z
dc.identifier.urihttps://hdl.handle.net/11508/61150
dc.identifier.volume35
dc.identifier.wosWOS:000303382400054
dc.identifier.wosqualityQ1
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherSpringer/Plenum Publishers
dc.relation.ispartofInflammation
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.snmzKA_WoS_20260511
dc.subjectnadroparin sodium
dc.subjectacetic acid-induced colitis
dc.subjectNrf2/HO-1 pathway
dc.subjectCOX-2
dc.titleNadroparin Sodium Activates Nrf2/HO-1 Pathway in Acetic Acid-Induced Colitis in Rats
dc.typeArticle

Dosyalar